This is a Validated Antibody Database (VAD) review about rat Pgr, based on 35 published articles (read how Labome selects the articles), using Pgr antibody in all methods. It is aimed to help Labome visitors find the most suited Pgr antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Pgr synonym: progesterone receptor; nuclear receptor subfamily 3 group C member 3

Invitrogen
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 1b
In order to determine if PIK3CA mutations contribute to tumor initiation, Invitrogen Pgr antibody (Thermo Scientific, RM-9102) was used in immunohistochemistry - paraffin section on mouse samples (fig 1b). Oncogenesis (2016) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:250; tbl 1
In order to classify triple-negative breast cancer into subtypes, Invitrogen Pgr antibody (Neomarkers, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:250 (tbl 1). Oncol Lett (2016) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; fig 4a
In order to describe the uterine transcriptome of patients with recurrent/repeated implantation failure, Invitrogen Pgr antibody (Thermo Fisher, PM-9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 4a). PLoS ONE (2016) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:300; loading ...
In order to explore the relationship between tumor-infiltrating lymphocytes and the clinical outcomes of triple-negative breast cancers, Invitrogen Pgr antibody (Thermoscientific, SP2) was used in immunohistochemistry on human samples at 1:300. Breast Cancer Res Treat (2016) ncbi
mouse monoclonal (Alpha PR6)
  • immunohistochemistry - paraffin section; mouse; tbl 2
In order to discuss the roles of somatostatin and cortistatin in mammary gland tumorigenesis and metabolic disorders, Invitrogen Pgr antibody (Thermo Scientific, MA1-411) was used in immunohistochemistry - paraffin section on mouse samples (tbl 2). Breast Cancer Res (2016) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1
In order to elucidate the role of Runx2 during the early stages of breast cancer and metastasis, Invitrogen Pgr antibody (Thermo Scientific, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Pathol Oncol Res (2016) ncbi
rabbit monoclonal (SP2)
  • immunocytochemistry; human; 1:10; fig 1b
In order to analyze propagation of oestrogen-responsive and oestrogen receptor-positive normal human breast cells in culture, Invitrogen Pgr antibody (Labvision, RM-9102-S) was used in immunocytochemistry on human samples at 1:10 (fig 1b). Nat Commun (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:1000; fig 6
In order to present two cases of primary sclerosing epithelioid fibrosarcoma of the kidney, Invitrogen Pgr antibody (Thermo, SP2) was used in immunohistochemistry on human samples at 1:1000 (fig 6). Diagn Pathol (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:100
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Invitrogen Pgr antibody (Thermo Scientific, RM-9102-S1) was used in immunohistochemistry on human samples at 1:100. Pathol Res Pract (2015) ncbi
rabbit monoclonal (SP2)
  • western blot; mouse; 1:200
In order to elucidate the potential of PIK3CA to induce multipotency during tumorigenesis in the mammary gland, Invitrogen Pgr antibody (Thermo Scientific, Rm9102) was used in western blot on mouse samples at 1:200. Nature (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 2
In order to characterize triple-negative breast cancer and the role of epithelial-mesenchymal transition markers, Invitrogen Pgr antibody (Thermo Lab Vision, RM-9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 2). Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (hPRa 7)
  • immunohistochemistry - paraffin section; mouse; fig 4
In order to propose that RANK dictates WNT responsiveness to hormone-induced changes in adult mammary cells, Invitrogen Pgr antibody (Thermo Scientific, MA5-12658) was used in immunohistochemistry - paraffin section on mouse samples (fig 4). Stem Cell Reports (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200
In order to assess the clinicopathological and immunohistochemical characteristics, and the clinical outcomes, between screen-detected and symptomatic DCIS, Invitrogen Pgr antibody (Thermo Scientific Lab Vision, RM-9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human
In order to discuss how to treat the four types of breast cancer, Invitrogen Pgr antibody (Thermo Scientific Lab Vision, SP2) was used in immunohistochemistry - paraffin section on human samples . Niger J Clin Pract (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:200
In order to evaluate the presence of cancer stem cells and EMT markers as prognostic markers for breast metaplastic carcinoma, Invitrogen Pgr antibody (Neomarker, RM-9102-S) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
rabbit monoclonal (SP2)
  • western blot; human; fig 3
In order to use a cell culture model for aromatase inhibitor-resistant breast cancer to show how fulvestrant treatment and cross-resistance between exemestane and letrozole shows sensitivity, Invitrogen Pgr antibody (Neomarkers, RM-9102) was used in western blot on human samples (fig 3). Int J Oncol (2015) ncbi
mouse monoclonal (Alpha PR6)
  • immunohistochemistry - paraffin section; mouse; 1:500
In order to study the role of progesterone on global stem cell function by serially transplanting mouse mammary epithelia, Invitrogen Pgr antibody (Thermo Fisher Scientific, MA1-411) was used in immunohistochemistry - paraffin section on mouse samples at 1:500. EMBO J (2015) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:200
In order to evaluate the prevalence, characteristics, prognosis, and effective treatment modalities in patients with primary squamous cell carcinoma of the breast, Invitrogen Pgr antibody (Zymed, SP2) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
rabbit monoclonal (SP2)
In order to examine possible factors that affect the type of breast cancer tumors in mice, Invitrogen Pgr antibody (Fisher Scientific, RM-9102-S0) was used . Cancer Res (2014) ncbi
mouse monoclonal (hPRa 7)
  • immunohistochemistry - paraffin section; mouse; 1:50
In order to study how Tip30 regulates FoxA1 expression and the differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell, Invitrogen Pgr antibody (Labvision, hPRa7) was used in immunohistochemistry - paraffin section on mouse samples at 1:50. Cell Death Dis (2014) ncbi
rabbit monoclonal (SP2)
  • immunocytochemistry; human; 1:25
  • immunohistochemistry; human; 1:25
In order to investigate the role of CEACAM6 in luminal, HER2-enriched, and basal-like breast cancers, Invitrogen Pgr antibody (Thermo Scientific, Sp2) was used in immunocytochemistry on human samples at 1:25 and in immunohistochemistry on human samples at 1:25. Am J Pathol (2014) ncbi
mouse monoclonal (hPRa 7)
  • immunocytochemistry; mouse
In order to enhance our understanding of Brca2, Pten and p53 in breast cancer development, Invitrogen Pgr antibody (ThermoScientific, hPRa7) was used in immunocytochemistry on mouse samples . J Pathol (2014) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:2000
In order to determine breast cancr stem cells and the lack of correlation of stem cell markers, Invitrogen Pgr antibody (LabVision, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:2000. Br J Cancer (2014) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human
  • immunocytochemistry; human
In order to study the role of TWIST1 in the mechanism by which KLF17 induces epithelial-to-mesenchymal transition in endometrioid endometrial cancer, Invitrogen Pgr antibody (Lab Vision, SP2) was used in immunohistochemistry - paraffin section on human samples and in immunocytochemistry on human samples . Carcinogenesis (2014) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; fig 2
In order to study triple negative breast cancer in Chinese women, Invitrogen Pgr antibody (Zymed, clone SP2) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). Int J Clin Exp Pathol (2013) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human
In order to report and characterize two cases of accessory breast cancer occurring concurrently with primary invasive breast cancer, Invitrogen Pgr antibody (Zymed, SP2) was used in immunohistochemistry on human samples . Cancer Biol Med (2012) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 2
In order to correlate expression of HER2, ER, PR, Ki-67, and CK5 with breast cancer reoccurrence, Invitrogen Pgr antibody (Neomarkers, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 2). Breast Cancer (Auckl) (2013) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:500; tbl 1
In order to study the expression of estrogen and progesterone receptors in low-grade ovarian serous carcinomas and the significance for hormone therapy, Invitrogen Pgr antibody (Thermo Scientific, SP2) was used in immunohistochemistry on human samples at 1:500 (tbl 1). Gynecol Oncol (2013) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; dog; 1:200
In order to measure the expression of ENO1 and assess its significance in canine mammary carcinoma, Invitrogen Pgr antibody (Thermo Scientific, SP2) was used in immunohistochemistry - paraffin section on dog samples at 1:200. BMC Vet Res (2011) ncbi
mouse monoclonal (hPRa 7)
  • western blot; human; 4 ug/ml; fig 5
In order to test the efficacy of mifepristone treatment on various cancers, Invitrogen Pgr antibody (Thermo Fisher, hPRa7) was used in western blot on human samples at 4 ug/ml (fig 5). BMC Cancer (2011) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry; mouse; 1:200; fig 1
In order to elucidate the contribution of PIK3CA H1047R to breast cancer pathogenesis, Invitrogen Pgr antibody (Thermo, RM-9102) was used in immunohistochemistry on mouse samples at 1:200 (fig 1). Cancer Res (2011) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200
In order to study EGFR gene in triple negative breast cancer and its therapeutic application, Invitrogen Pgr antibody (Neomarker, RM9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res (2011) ncbi
rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:250; fig 2, 3, 4
  • immunohistochemistry; human; 1:250
In order to report a new clinical case of prostatic adenomas with abnormal p63 expression, Invitrogen Pgr antibody (NeoMarkers, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 2, 3, 4) and in immunohistochemistry on human samples at 1:250. Int J Surg Pathol (2011) ncbi
Abcam
rabbit monoclonal (SP2)
  • immunohistochemistry; rat; 1:100; loading ...; fig 3d
Abcam Pgr antibody (Abcam, ab16661) was used in immunohistochemistry on rat samples at 1:100 (fig 3d). PLoS Genet (2019) ncbi
Santa Cruz Biotechnology
mouse monoclonal (AB-52)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
Santa Cruz Biotechnology Pgr antibody (Santa Cruz, sc-810) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Arch Med Sci (2017) ncbi
Articles Reviewed
  1. Ding L, Shunkwiler L, Harper N, Zhao Y, Hinohara K, Huh S, et al. Deletion of Cdkn1b in ACI rats leads to increased proliferation and pregnancy-associated changes in the mammary gland due to perturbed systemic endocrine environment. PLoS Genet. 2019;15:e1008002 pubmed publisher
  2. Méndez López L, Zavala Pompa A, Cortés Gutiérrez E, Cerda Flores R, Dávila Rodríguez M. Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors. Arch Med Sci. 2017;13:228-235 pubmed publisher
  3. Sheen M, Marotti J, Allegrezza M, Rutkowski M, Conejo Garcia J, Fiering S. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 2016;5:e267 pubmed publisher
  4. Liu Y, Wang K, Xing H, Zhai X, Wang L, Wang W. Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol Lett. 2016;12:1240-1256 pubmed
  5. Choi Y, Kim H, Lim E, Park M, Yoon J, Kim Y, et al. Integrative Analyses of Uterine Transcriptome and MicroRNAome Reveal Compromised LIF-STAT3 Signaling and Progesterone Response in the Endometrium of Patients with Recurrent/Repeated Implantation Failure (RIF). PLoS ONE. 2016;11:e0157696 pubmed publisher
  6. Matsumoto H, Thike A, Li H, Yeong J, Koo S, Dent R, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156:237-47 pubmed publisher
  7. Luque R, Villa Osaba A, L López F, Pozo Salas A, Sánchez Sánchez R, Ortega Salas R, et al. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res. 2016;18:29 pubmed publisher
  8. El Gendi S, Mostafa M. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma. Pathol Oncol Res. 2016;22:461-70 pubmed publisher
  9. Fridriksdottir A, Kim J, Villadsen R, Klitgaard M, Hopkinson B, Petersen O, et al. Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture. Nat Commun. 2015;6:8786 pubmed publisher
  10. Ertoy Baydar D, Kosemehmetoglu K, Aydin O, Bridge J, Buyukeren B, Aki F. Primary sclerosing epithelioid fibrosarcoma of kidney with variant histomorphologic features: report of 2 cases and review of the literature. Diagn Pathol. 2015;10:186 pubmed publisher
  11. KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed publisher
  12. Koren S, Reavie L, Couto J, De Silva D, Stadler M, Roloff T, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature. 2015;525:114-8 pubmed publisher
  13. Cheung S, Boey Y, Koh V, Thike A, Lim J, Iqbal J, et al. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:489-98 pubmed publisher
  14. Joshi P, Waterhouse P, Kannan N, Narala S, Fang H, Di Grappa M, et al. RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. Stem Cell Reports. 2015;5:31-44 pubmed publisher
  15. Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152:293-304 pubmed publisher
  16. Nwafor C, Keshinro S. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger J Clin Pract. 2015;18:553-8 pubmed publisher
  17. Oon M, Thike A, Tan S, Tan P. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast Cancer Res Treat. 2015;150:31-41 pubmed publisher
  18. Hole S, Pedersen A, Hansen S, Lundqvist J, Yde C, Lykkesfeldt A. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. 2015;46:1481-90 pubmed publisher
  19. Rajaram R, Buric D, Caikovski M, Ayyanan A, Rougemont J, Shan J, et al. Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk. EMBO J. 2015;34:641-52 pubmed publisher
  20. Liu J, Yu Y, Sun J, He S, Wang X, Yin J, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015;149:133-40 pubmed publisher
  21. Nguyen D, Ouyang H, Mao J, Hlatky L, Barcellos Hoff M. Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice. Cancer Res. 2014;74:7149-58 pubmed publisher
  22. Chen F, Li A, Gao S, Hollern D, Williams M, Liu F, et al. Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression. Cell Death Dis. 2014;5:e1242 pubmed publisher
  23. Balk Møller E, Kim J, Hopkinson B, Timmermans Wielenga V, Petersen O, Villadsen R. A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched. Am J Pathol. 2014;184:1198-208 pubmed publisher
  24. Melchor L, Molyneux G, Mackay A, Magnay F, Atienza M, Kendrick H, et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol. 2014;233:124-37 pubmed publisher
  25. Liu Y, Nenutil R, Appleyard M, Murray K, Boylan M, Thompson A, et al. Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer. 2014;110:2063-71 pubmed publisher
  26. Dong P, Kaneuchi M, Xiong Y, Cao L, Cai M, Liu X, et al. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis. 2014;35:760-8 pubmed publisher
  27. Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013;6:1380-91 pubmed
  28. Hao J, Yang C, Liu F, Yang Y, Li S, Li W, et al. Accessory breast cancer occurring concurrently with bilateral primary invasive breast carcinomas: a report of two cases and literature review. Cancer Biol Med. 2012;9:197-201 pubmed publisher
  29. Joensuu K, Leidenius M, Kero M, Andersson L, Horwitz K, Heikkila P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl). 2013;7:23-34 pubmed publisher
  30. Escobar J, Klimowicz A, Dean M, Chu P, Nation J, Nelson G, et al. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol. 2013;128:371-6 pubmed publisher
  31. Chu P, Hsu N, Liao A, Shih N, Hou M, Liu C. Overexpression of ?-enolase correlates with poor survival in canine mammary carcinoma. BMC Vet Res. 2011;7:62 pubmed publisher
  32. Tieszen C, Goyeneche A, Brandhagen B, Ortbahn C, Telleria C. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 2011;11:207 pubmed publisher
  33. Meyer D, Brinkhaus H, Müller U, Muller M, Cardiff R, Bentires Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res. 2011;71:4344-51 pubmed publisher
  34. Teng Y, Tan W, Thike A, Cheok P, Tse G, Wong N, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35 pubmed publisher
  35. Baydar D, Kulac I, Gurel B, De Marzo A. A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis. Int J Surg Pathol. 2011;19:131-6 pubmed publisher